Hayder Kadhim: Determinants and Outcomes of OAC Discontinuation in Atrial Fibrillation
Hayder Kadhim, Consultant Cardiologist at Region Östergötland, shared a post on LinkedIn:
”I am pleased and honored to present our latest study as a poster at the prestigious ESOC Conference in Maastricht.
Our research explores risk factors associated with oral anticoagulant (OAC) interruptions in patients with non-valvular atrial fibrillation (NVAF), including both temporary and permanent discontinuations.
We also examine treatment pattern changes across different OAC types and dosing strategies, and compare clinical outcomes between patients who persist with therapy and those who discontinue.
This work is based on high-quality Swedish national registers, including AURICULA, which uniquely enabled us to identify the exact dates of treatment discontinuation and generate robust real-world evidence.”

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines